Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Wilms Tumor 1Testicular Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Familial ependymoma 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1Brain Neoplasms 1Astrocytoma 1

Interventions

Irinotecan 30Gemcitabine 25Paclitaxel 24Cisplatin 24Docetaxel 19Oxaliplatin 15Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 12Capecitabine 12Bortezomib 10Taxes 83-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Topotecan 6Temozolomide 6Immunohistochemistry 6Immunoenzyme Techniques 6Bevacizumab 67-hydroxystaurosporine 6tanespimycin 5Sorafenib 5Pharmacogenomic Testing 5Pemetrexed 5Etoposide 5Chromatography, High Pressure Liquid 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unspecified Adult Solid Tumor, Protocol Specific × trioctyl phosphine oxide × Clear all
NCT00541359 2017-08-09

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

City of Hope Medical Center

Phase 1 Completed
54 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡